Qingxiao Liang

Qingxiao Liang

Auto-generated profile, based on publicly available information

Qingxiao Liang

Chongqing Key Laboratory of Molecular Oncology and Epigenetics The First Affiliated Hospital of Chongqing Medical University Chongqing China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 November 2024 in BioFactors
Verified
Journal Article
Closed access
BYBicheng Ye
Bicheng Ye
AJAimin Jiang
Aimin Jiang
FLFeng Liang
Feng Liang
CWChangcheng Wang
Changcheng Wang
XLXiaoqing Liang
Xiaoqing Liang
PZPengpeng Zhang
Pengpeng Zhang

16 October 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
BYBicheng Ye
Bicheng Ye
JFJun Fan
Jun Fan
QMQingren Meng
Qingren Meng
QLQingxiao Liang
Qingxiao Liang
AJAimin Jiang
Aimin Jiang
PZPengpeng Zhang
Pengpeng Zhang
Background Immune checkpoint inhibitor (ICI) therapy efficacy varies among cancer patients, necessitating precise predictive biomarkers for optimized treatment strategies. Methods We developed the Adaptive best subset selection algorithm and Genetic algorithm Aided Ensemble learning (AGAE) score through multi-cohort transcriptomic analysis of ICI-treated patients. The AGAE score incorporated gene-pairing, Adaptive Best Subset Selection for feature optimization, and a Genetic Algorithm for optimal basic learner identification. We explored correlations between AGAE score and immune microenvironments using multi-omics data. Potential targets were screened using 17 CRISPR datasets and validated through in vitro and in vivo experiments. Results The AGAE score demonstrated robust predictive power for ICI therapy outcomes, with lower scores correlating with enhanced treatment response. The AGAE score outperformed published signatures and conventional biomarkers. Lower AGAE scores were associated with increased immune cell infiltration, higher immunogenicity, and enhanced antitumor immune activity. The CEP55 was identified as a potential key target driving immune evasion through AGAE scoring and CRISPR screening. Experimental validation showed CEP55 downregulation attenuated tumor cell malignancy and augmented ICI therapy efficacy by modulating T cell responses. Conclusions The AGAE score was a potent predictor of ICI therapy efficacy, facilitating refined patient stratification. CEP55’s role in the tumor microenvironment’s immune response highlights its potential as a therapeutic target. Targeted interventions against CEP55 may improve immunotherapy precision.